Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI
NCT ID: NCT03173287
Last Updated: 2017-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
63 participants
INTERVENTIONAL
2017-03-01
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
NCT03142698
Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging
NCT02480972
Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease
NCT03245606
Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis
NCT01572064
Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis
NCT01981421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective of this study is to show that the measured perfusion-related scattering value (D \*) is related to the hepatic fibrosis stage.
Secondary objectives
* Evaluation of infusion fraction (f) and fibrosis stage.
* Evaluation of molecular diffusion (D) and fibrosis stage.
* Evaluation of ADC and fibrosis stage.
* Assess whether there is a link between the etiology of fibrosis and the value of the diffusion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with hepatic biopsy
The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
Quantification of liver fibrosis
Procedure MRI and liver biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quantification of liver fibrosis
Procedure MRI and liver biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signature of written consent
Exclusion Criteria
* Refusal of protocol
* Underage patients and protected adults
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benoit MAGNIN
Role: PRINCIPAL_INVESTIGATOR
CHU de Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A02066-45
Identifier Type: OTHER
Identifier Source: secondary_id
CHU-327
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.